First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
17 juin 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
10 mai 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, May 10, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
15 mars 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
21 janv. 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08 sept. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
Prosensa Awarded $200,000 Research Grant from PPMD
27 juin 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
25 juin 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
13 mai 2014 08h57 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, May 20,...
Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference
28 avr. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
CureDuchenne Announces Third Annual Scientific Summit and Worlwide Webcast
24 janv. 2012 13h51 HE
|
CureDuchenne
NEWPORT BEACH, Calif., Jan. 24, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, a lethal muscle disease that affects...